Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

Reece DE, Trieu Y, Masih-Khan E, Atenafu EG, Chen C, Prica A, Tiedemann R, Trudel S, Kukreti V.

Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):387-94. doi: 10.1016/j.clml.2016.04.012. Epub 2016 May 10.

PMID:
27349765
2.

D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.

Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, Reece D, Stewart KA, Trieu Y, Trudel S, Chen CI.

Br J Haematol. 2013 Jun;161(6):802-10. doi: 10.1111/bjh.12325. Epub 2013 Apr 18.

PMID:
23594335
3.

Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.

Prica A, Trieu Y, Xu W, Reece DE, Trudel S, Kukreti V, Chen C.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):25-31. doi: 10.1016/j.clml.2012.08.008. Epub 2012 Oct 27.

PMID:
23107916
4.

Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.

Jiang N, Qi C, Trieu Y, Reece D, Chang H.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1790-5. doi: 10.1016/j.bbmt.2011.05.009. Epub 2011 May 20.

5.

Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.

Liang SB, Yang XZ, Trieu Y, Li Z, Zive J, Leung-Hagesteijn C, Wei E, Zozulya S, Coss CC, Dalton JT, Fantus IG, Trudel S.

Clin Cancer Res. 2011 Jul 15;17(14):4693-704. doi: 10.1158/1078-0432.CCR-10-3097. Epub 2011 Jun 1.

6.

Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

Chang H, Jiang A, Qi C, Trieu Y, Chen C, Reece D.

Leuk Lymphoma. 2010 Nov;51(11):2084-91. doi: 10.3109/10428194.2010.524325. Epub 2010 Oct 7.

PMID:
20929319
7.

Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.

Chang H, Trieu Y, Qi X, Jiang NN, Xu W, Reece D.

Leuk Res. 2011 Jan;35(1):95-8. doi: 10.1016/j.leukres.2010.05.002. Epub 2010 May 26.

PMID:
20537706
8.

Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study.

Chang H, Qi C, Trieu Y, Jiang A, Young KH, Chesney A, Jani P, Wang C, Reece D, Chen C.

Clin Lymphoma Myeloma. 2009 Mar;9(1):36-8. doi: 10.3816/CLM.2009.n.008.

PMID:
19362968
9.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, Mansoor A, Chen C, Masih-Khan E, Trieu Y, Bruyere H, Stewart DA, Bahlis NJ.

Blood. 2009 Jul 16;114(3):522-5. doi: 10.1182/blood-2008-12-193458. Epub 2009 Mar 30.

10.

The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y, Reece D, Paterson J, Wang D, Wen XY.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):621-9.

11.

Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.

Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D.

Leuk Res. 2007 Jun;31(6):779-82. Epub 2006 Sep 22.

PMID:
16996589
12.

Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.

Chang H, Qi X, Trieu Y, Xu W, Reader JC, Ning Y, Reece D.

Br J Haematol. 2006 Nov;135(4):486-91. Epub 2006 Sep 22.

PMID:
16995883
13.
14.

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.

Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J, Reece D, Chen C, Stewart AK.

J Clin Oncol. 2005 Oct 1;23(28):7069-73. Epub 2005 Aug 29.

PMID:
16129840
15.

The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades.

Zhu YX, Benn S, Li ZH, Wei E, Masih-Khan E, Trieu Y, Bali M, McGlade CJ, Claudio JO, Stewart AK.

J Exp Med. 2004 Sep 20;200(6):737-47.

16.

Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.

Trieu Y, Wen XY, Skinnider BF, Bray MR, Li Z, Claudio JO, Masih-Khan E, Zhu YX, Trudel S, McCart JA, Mak TW, Stewart AK.

Cancer Res. 2004 May 1;64(9):3271-5.

Supplemental Content

Support Center